益佰制药：2025年度公司经营业绩将出现亏损

Core Viewpoint - Yibai Pharmaceutical (600594) expects to report a net loss attributable to shareholders for the fiscal year 2025, with specific figures yet to be disclosed [1] Financial Performance - The company's financial department has conducted preliminary assessments confirming that operating performance will face losses [1] - Yibai Pharmaceutical will expedite its financial accounting processes and aims to disclose the 2025 performance forecast within the stipulated timeframe [1] - The final financial data will be based on the formally disclosed audited annual report [1]